RxDoctor Payments Data

Moneal Shah, MD

Cardiovascular Disease · Pittsburgh, PANPI 1609092691

Payments from drug & device makers

$130,322in general payments, 2019–2025

Across 354 payments — averaging $368.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$124K
  • Amgen$1K
  • E.r. Squibb & Sons, L.L.C.$795
  • Novartis$436
  • Medtronic$432
  • Pfizer$417
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$14,48316%
  • Speaking & faculty fees$57,08463%
  • Travel & lodging$9,64411%
  • Food & beverage$9,21110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,322 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$68,295
Medicare patients
488
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$160,620
EntrestoSacubitril/Valsartan72$76,126
JardianceEmpagliflozin54$62,741
XareltoRivaroxaban41$38,643
Repatha SureclickEvolocumab50$31,467
Ranolazine ErRanolazine53$5,060
BrilintaTicagrelor11$4,940
Atorvastatin Calcium258$3,079
Ezetimibe139$2,360
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$2,345
Rosuvastatin Calcium133$1,636
Metoprolol Succinate81$1,403
Isosorbide Mononitrate ErIsosorbide Mononitrate77$1,000
Flecainide Acetate12$737
Amlodipine Besylate152$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$417$160,620136 claims
NovartisEntresto$436$76,12672 claims
Boehringer IngelheimJardiance$391$62,74154 claims
Johnson & JohnsonXarelto$395$38,64341 claims
AstraZenecaBrilinta$376$4,94011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →